Rachel K. King - Net Worth and Insider Trading

Rachel K. King Net Worth

The estimated net worth of Rachel K. King is at least $244,921 dollars as of 2024-06-04. Rachel K. King is the President, CEO of GlycoMimetics Inc and owns about 531,206 shares of GlycoMimetics Inc (GLYC) stock worth over $156,121. Rachel K. King is also the Director of Novavax Inc and owns about 5,000 shares of Novavax Inc (NVAX) stock worth over $88,800. Details can be seen in Rachel K. King's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Rachel K. King has not made any transactions after 2021-05-19 and currently still holds the listed stock(s).

Transaction Summary of Rachel K. King

To

Rachel K. King Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Rachel K. King owns 2 companies in total, including Novavax Inc (NVAX) , and GlycoMimetics Inc (GLYC) .

Click here to see the complete history of Rachel K. King’s form 4 insider trades.

Insider Ownership Summary of Rachel K. King

Ticker Comapny Transaction Date Type of Owner
NVAX Novavax Inc 2021-05-19 director
GLYC GlycoMimetics Inc 2020-12-28 director & President & CEO

Rachel K. King Latest Holdings Summary

Rachel K. King currently owns a total of 2 stocks. Among these stocks, Rachel K. King owns 531,206 shares of GlycoMimetics Inc (GLYC) as of December 28, 2020, with a value of $156,121 and a weighting of 63.74%. Rachel K. King also owns 5,000 shares of Novavax Inc (NVAX) as of May 19, 2021, with a value of $88,800 and a weighting of 36.26%.

Latest Holdings of Rachel K. King

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
GLYC GlycoMimetics Inc 2020-12-28 531,206 0.29 156,121
NVAX Novavax Inc 2021-05-19 5,000 17.76 88,800

Holding Weightings of Rachel K. King


Rachel K. King Form 4 Trading Tracker

According to the SEC Form 4 filings, Rachel K. King has made a total of 1 transactions in GlycoMimetics Inc (GLYC) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in GlycoMimetics Inc is the sale of 84,176 shares on December 28, 2020, which brought Rachel K. King around $329,128.

According to the SEC Form 4 filings, Rachel K. King has made a total of 1 transactions in Novavax Inc (NVAX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Novavax Inc is the acquisition of 700 shares on May 19, 2021, which cost Rachel K. King around $97,748.

Insider Trading History of Rachel K. King

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Rachel K. King Trading Performance

GuruFocus tracks the stock performance after each of Rachel K. King's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Rachel K. King is 5.53%. GuruFocus also compares Rachel K. King's trading performance to market benchmark return within the same time period. The performance of stocks bought by Rachel K. King within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Rachel K. King's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Rachel K. King

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 7.58 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 4.57 LIMIT LIMIT LIMIT LIMIT LIMIT

Rachel K. King Ownership Network

Ownership Network List of Rachel K. King

No Data

Ownership Network Relation of Rachel K. King

Insider Network Chart

Rachel K. King Owned Company Details

What does Novavax Inc do?

Who are the key executives at Novavax Inc?

Rachel K. King is the director of Novavax Inc. Other key executives at Novavax Inc include President & R&D Filip Dubovsky , President & R&D Gregory M Glenn , and EVP & Chief Strategy Officer Elaine O'hara .

Novavax Inc (NVAX) Insider Trades Summary

Over the past 18 months, Rachel K. King made no insider transaction in Novavax Inc (NVAX). Other recent insider transactions involving Novavax Inc (NVAX) include a net sale of 47,312 shares made by Filip Dubovsky , and a net purchase of 6,000 shares made by Gregory M Glenn .

In summary, during the past 3 months, insiders sold 47,312 shares of Novavax Inc (NVAX) in total and bought 0 shares, with a net sale of 47,312 shares. During the past 18 months, 47,312 shares of Novavax Inc (NVAX) were sold and 6,000 shares were bought by its insiders, resulting in a net sale of 41,312 shares.

Novavax Inc (NVAX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Novavax Inc Insider Transactions

No Available Data

Rachel K. King Mailing Address

Above is the net worth, insider trading, and ownership report for Rachel K. King. You might contact Rachel K. King via mailing address: C/o Glycomimetics, Inc., 401 Professional Drive, Suite 250, Gaithersburg Md 20879.

Discussions on Rachel K. King

No discussions yet.